TRIUMPH: what the trials say vs what this community says
TRIUMPH: what the trials say vs what this community says. It is the sort of thing everyone half-believes and nobody writes down.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
The fatigue profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.
Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
the glucagon component is why the metabolic story reads differently
Disagree.
discount_math_dm is right about the escalation being the variable. It explains most of the difficult reports here.
research-use-only material is not approved for human use, full stop
Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
the escalation is where most of the reported trouble sits
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.
Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
Are you comparing against phase 3 numbers for something else? They are not comparable.
Which phase 2 arm are you quoting, and at what week?
heart rate is the thing people report watching
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
not approved anywhere, which is the single most important fact in this board
a lot of the confident posting here is extrapolation
- 1Nothing containing this compound is approved anywhere. Research-use-only…7 comments in this branch · started by u/cagrilintide_enthusiast